Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies Journal Article


Authors: Hoseini, S. S.; Cheung, N. K. V.
Article Title: Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies
Abstract: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide with an overall survival rate of less than 15% in developed countries. Despite attempts at new therapeutic strategies, the majority of patients succumb to this cancer. Buttressed by the highly successful clinical impact in melanoma, immunotherapy is gaining momentum as the next treatment modality for many human cancers. Chimeric antigen receptors (CAR) contain the antigen binding moieties of a monoclonal antibody and the co-stimulatory and signaling domains associated with effector receptor signaling. Bispecific antibodies (BsAb) combine the binding specificities of two different monoclonal antibodies, one activating a receptor on a killer effector cell, while the other engaging a tumor-associated antigen to initiate tumor cytotoxicity. In this review, we survey the HCC targets for which CARs and bispecific antibodies have been generated. The pros and cons of these targets for T-cell and Natural Killer cell based immunotherapy will be discussed. © 2017
Keywords: hepatocellular carcinoma; treatment; chimeric antigen receptor; bispecific antibody
Journal Title: Cancer Letters
Volume: 399
ISSN: 0304-3835
Publisher: Elsevier Ireland Ltd.  
Date Published: 2017-07-28
Start Page: 44
End Page: 52
Language: English
DOI: 10.1016/j.canlet.2017.04.013
PROVIDER: scopus
PUBMED: 28428075
PMCID: PMC5496242
DOI/URL:
Notes: Short Survey -- Export Date: 2 June 2017 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Nai-Kong Cheung
    530 Cheung